Cargando…

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease

IMPORTANCE: Deposition of the pathological α-synuclein (αSyn(P)) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic ampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zerui, Becker, Katelyn, Donadio, Vincenzo, Siedlak, Sandra, Yuan, Jue, Rezaee, Masih, Incensi, Alex, Kuzkina, Anastasia, Orrú, Christina D., Tatsuoka, Curtis, Liguori, Rocco, Gunzler, Steven A., Caughey, Byron, Jimenez-Capdeville, Maria E., Zhu, Xiongwei, Doppler, Kathrin, Cui, Li, Chen, Shu G., Ma, Jiyan, Zou, Wen-Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522783/
https://www.ncbi.nlm.nih.gov/pubmed/32986090
http://dx.doi.org/10.1001/jamaneurol.2020.3311
_version_ 1783588256731889664
author Wang, Zerui
Becker, Katelyn
Donadio, Vincenzo
Siedlak, Sandra
Yuan, Jue
Rezaee, Masih
Incensi, Alex
Kuzkina, Anastasia
Orrú, Christina D.
Tatsuoka, Curtis
Liguori, Rocco
Gunzler, Steven A.
Caughey, Byron
Jimenez-Capdeville, Maria E.
Zhu, Xiongwei
Doppler, Kathrin
Cui, Li
Chen, Shu G.
Ma, Jiyan
Zou, Wen-Quan
author_facet Wang, Zerui
Becker, Katelyn
Donadio, Vincenzo
Siedlak, Sandra
Yuan, Jue
Rezaee, Masih
Incensi, Alex
Kuzkina, Anastasia
Orrú, Christina D.
Tatsuoka, Curtis
Liguori, Rocco
Gunzler, Steven A.
Caughey, Byron
Jimenez-Capdeville, Maria E.
Zhu, Xiongwei
Doppler, Kathrin
Cui, Li
Chen, Shu G.
Ma, Jiyan
Zou, Wen-Quan
author_sort Wang, Zerui
collection PubMed
description IMPORTANCE: Deposition of the pathological α-synuclein (αSyn(P)) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays can sensitively detect skin biomarkers for PD and non-PD synucleinopathies remains unknown. OBJECTIVE: To develop sensitive and specific skin biomarkers for antemortem diagnosis of PD and other synucleinopathies. DESIGN, SETTING, AND PARTICIPANTS: This retrospective and prospective diagnostic study evaluated autopsy and biopsy skin samples from neuropathologically and clinically diagnosed patients with PD and controls without PD. Autopsy skin samples were obtained at 3 medical centers from August 2016 to September 2019, and biopsy samples were collected from 3 institutions from August 2018 to November 2019. Based on neuropathological and clinical diagnoses, 57 cadavers with synucleinopathies and 73 cadavers with nonsynucleinopathies as well as 20 living patients with PD and 21 living controls without PD were included. Specifically, cadavers and participants had PD, LBD, MSA, Alzheimer disease, progressive supranuclear palsy, or corticobasal degeneration or were nonneurodegenerative controls (NNCs). A total of 8 approached biopsy participants either refused to participate in or were excluded from this study due to uncertain clinical diagnosis. Data were analyzed from September 2019 to April 2020. MAIN OUTCOMES AND MEASURES: Skin αSyn(P) seeding activity was analyzed by RT-QuIC and PMCA assays. RESULTS: A total of 160 autopsied skin specimens from 140 cadavers (85 male cadavers [60.7%]; mean [SD] age at death, 76.8 [10.1] years) and 41 antemortem skin biopsies (27 male participants [66%]; mean [SD] age at time of biopsy, 65.3 [9.2] years) were analyzed. RT-QuIC analysis of αSyn(P) seeding activity in autopsy abdominal skin samples from 47 PD cadavers and 43 NNCs revealed 94% sensitivity (95% CI, 85-99) and 98% specificity (95% CI, 89-100). As groups, RT-QuIC also yielded 93% sensitivity (95% CI, 85-97) and 93% specificity (95% CI, 83-97) among 57 cadavers with synucleinopathies (PD, LBD, and MSA) and 73 cadavers without synucleinopathies (Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, and NNCs). PMCA showed 82% sensitivity (95% CI, 76-88) and 96% specificity (95% CI, 85-100) with autopsy abdominal skin samples from PD cadavers. From posterior cervical and leg skin biopsy tissues from patients with PD and controls without PD, the sensitivity and specificity were 95% (95% CI, 77-100) and 100% (95% CI, 84-100), respectively, for RT-QuIC and 80% (95% CI, 49-96) and 90% (95% CI, 60-100) for PMCA. CONCLUSIONS AND RELEVANCE: This study provides proof-of-concept that skin αSyn(P) seeding activity may serve as a novel biomarker for antemortem diagnoses of PD and other synucleinopathies.
format Online
Article
Text
id pubmed-7522783
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-75227832020-10-05 Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease Wang, Zerui Becker, Katelyn Donadio, Vincenzo Siedlak, Sandra Yuan, Jue Rezaee, Masih Incensi, Alex Kuzkina, Anastasia Orrú, Christina D. Tatsuoka, Curtis Liguori, Rocco Gunzler, Steven A. Caughey, Byron Jimenez-Capdeville, Maria E. Zhu, Xiongwei Doppler, Kathrin Cui, Li Chen, Shu G. Ma, Jiyan Zou, Wen-Quan JAMA Neurol Original Investigation IMPORTANCE: Deposition of the pathological α-synuclein (αSyn(P)) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays can sensitively detect skin biomarkers for PD and non-PD synucleinopathies remains unknown. OBJECTIVE: To develop sensitive and specific skin biomarkers for antemortem diagnosis of PD and other synucleinopathies. DESIGN, SETTING, AND PARTICIPANTS: This retrospective and prospective diagnostic study evaluated autopsy and biopsy skin samples from neuropathologically and clinically diagnosed patients with PD and controls without PD. Autopsy skin samples were obtained at 3 medical centers from August 2016 to September 2019, and biopsy samples were collected from 3 institutions from August 2018 to November 2019. Based on neuropathological and clinical diagnoses, 57 cadavers with synucleinopathies and 73 cadavers with nonsynucleinopathies as well as 20 living patients with PD and 21 living controls without PD were included. Specifically, cadavers and participants had PD, LBD, MSA, Alzheimer disease, progressive supranuclear palsy, or corticobasal degeneration or were nonneurodegenerative controls (NNCs). A total of 8 approached biopsy participants either refused to participate in or were excluded from this study due to uncertain clinical diagnosis. Data were analyzed from September 2019 to April 2020. MAIN OUTCOMES AND MEASURES: Skin αSyn(P) seeding activity was analyzed by RT-QuIC and PMCA assays. RESULTS: A total of 160 autopsied skin specimens from 140 cadavers (85 male cadavers [60.7%]; mean [SD] age at death, 76.8 [10.1] years) and 41 antemortem skin biopsies (27 male participants [66%]; mean [SD] age at time of biopsy, 65.3 [9.2] years) were analyzed. RT-QuIC analysis of αSyn(P) seeding activity in autopsy abdominal skin samples from 47 PD cadavers and 43 NNCs revealed 94% sensitivity (95% CI, 85-99) and 98% specificity (95% CI, 89-100). As groups, RT-QuIC also yielded 93% sensitivity (95% CI, 85-97) and 93% specificity (95% CI, 83-97) among 57 cadavers with synucleinopathies (PD, LBD, and MSA) and 73 cadavers without synucleinopathies (Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, and NNCs). PMCA showed 82% sensitivity (95% CI, 76-88) and 96% specificity (95% CI, 85-100) with autopsy abdominal skin samples from PD cadavers. From posterior cervical and leg skin biopsy tissues from patients with PD and controls without PD, the sensitivity and specificity were 95% (95% CI, 77-100) and 100% (95% CI, 84-100), respectively, for RT-QuIC and 80% (95% CI, 49-96) and 90% (95% CI, 60-100) for PMCA. CONCLUSIONS AND RELEVANCE: This study provides proof-of-concept that skin αSyn(P) seeding activity may serve as a novel biomarker for antemortem diagnoses of PD and other synucleinopathies. American Medical Association 2020-09-28 2021-01 /pmc/articles/PMC7522783/ /pubmed/32986090 http://dx.doi.org/10.1001/jamaneurol.2020.3311 Text en Copyright 2020 Wang Z et al. JAMA Neurology. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Wang, Zerui
Becker, Katelyn
Donadio, Vincenzo
Siedlak, Sandra
Yuan, Jue
Rezaee, Masih
Incensi, Alex
Kuzkina, Anastasia
Orrú, Christina D.
Tatsuoka, Curtis
Liguori, Rocco
Gunzler, Steven A.
Caughey, Byron
Jimenez-Capdeville, Maria E.
Zhu, Xiongwei
Doppler, Kathrin
Cui, Li
Chen, Shu G.
Ma, Jiyan
Zou, Wen-Quan
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title_full Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title_fullStr Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title_full_unstemmed Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title_short Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
title_sort skin α-synuclein aggregation seeding activity as a novel biomarker for parkinson disease
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522783/
https://www.ncbi.nlm.nih.gov/pubmed/32986090
http://dx.doi.org/10.1001/jamaneurol.2020.3311
work_keys_str_mv AT wangzerui skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT beckerkatelyn skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT donadiovincenzo skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT siedlaksandra skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT yuanjue skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT rezaeemasih skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT incensialex skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT kuzkinaanastasia skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT orruchristinad skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT tatsuokacurtis skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT liguorirocco skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT gunzlerstevena skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT caugheybyron skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT jimenezcapdevillemariae skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT zhuxiongwei skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT dopplerkathrin skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT cuili skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT chenshug skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT majiyan skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease
AT zouwenquan skinasynucleinaggregationseedingactivityasanovelbiomarkerforparkinsondisease